期刊文献+

着丝粒蛋白L表达与肝移植术后肝细胞癌复发的关联性研究 被引量:1

A study on correlation between expression of centromeric protein L and recurrence of hepatocellular carcinoma after liver transplantation
下载PDF
导出
摘要 目的 探讨着丝粒蛋白L(CENPL)表达与肝移植术后肝细胞癌复发的关联性。方法 选择2014年1月至2020年6月在福建中医药大学附属第三人民医院、联勤保障部队第九〇〇医院和广西壮族自治区人民医院行肝移植术并术后肝细胞癌复发患者93例(复发组)。选择同期行肝移植手术但术后未复发的肝细胞癌患者46例(未复发组)。采用免疫组化染色法观察肝细胞癌组织和癌旁组织CENPL表达情况。分析CENPL表达与患者临床病理指标及生存预后的关联性。结果 光镜下可见癌组织CENPL染色呈阳性,主要表达在细胞核部位,少量在细胞质表达。多因素Cox回归分析结果显示,以CNLCⅡ期为参照,CNLCⅠ期是肝移植后肝癌复发的抑制因素[HR(95%CI)=0.46(0.13~0.91),P=0.013];以CENPL低表达为参照,CENPL高表达是肝移植后肝癌复发的促进因素[HR(95%CI)=1.68(1.41~2.99),P=0.003]。CENPL高表达组的中位无复发生存期(RFS)为5(3~22)个月,低表达组中位RFS为8(5~26)个月,两组差异有统计学意义(log-rank检验:χ~2=9.269,P=0.002)。CENPL高表达组中位总生存期(OS)为14(8~40)个月,低表达组中位OS为22(9~37)个月,两组差异有统计学意义(log-rank检验:χ~2=4.406,P=0.031)。结论 CENPL对肝移植术后肝细胞癌复发有预测价值,值得进一步研究。 Objective To investigate the correlation between the expression of centromeric protein L(CENPL)and the recurrence of hepatocellular carcinoma after liver transplantation.Methods A total of 93 patients with recurrent hepatocellular carcinoma who underwent liver transplantation in the Third People′s Hospital Affiliated to Fujian University of Traditional Chinese Medicine,the 900th Hospital of the Joint Logistic Support Force of Chinese People′s Liberation Army and the People′s Hospital of Guangxi Zhuang Autonomous Region from January 2014 to June 2020 were selected as the recurrence group.Forty-six patients with hepatocellular carcinoma who underwent liver transplantation at the same time but did not relapse after operation were selected as the non-recurrence group.Immunohistochemical staining method was used to observe the expressions of CENPL in hepatocellular carcinoma tissues and their adjacent tissues.The correlation between the expression of CENPL and the clinicopathological indicators and survival prognosis was analyzed.Results Microscopically,CENPL staining was positive in the cancer tissues,mainly expressed in the nucleus,and a small amount of CENPL was expressed in the cytoplasm.The results of multivariate Cox regression analysis showed that China Liver Cancer Staging(CNLC)stageⅠwas an inhibitory factor for HCC recurrence after liver transplantation with CNLC stageⅡas the reference[HR(95%CI)=0.46(0.13-0.91),P=0.013],and the high expression of CENPL was a promoting factor for HCC recurrence after liver transplantation with the low expression of CENPL as the reference[HR(95%CI)=1.68(1.41-2.99),P=0.003].The median recurrence-free survival(RFS)of the high CENPL expression group was 5(3-22)months,and the median RFS of the low CENPL expression group was 8(5-26)months,and the difference was statistically significant between the two groups(log-rank test:χ2=9.269,P=0.002).The median overall survival(OS)of the high CENPL expression group was 14(8-40)months,and the median OS of the low CENPL expression group was 22(9-37)months,and the difference was statistically significant between the two groups(log-rank test:χ2=4.406,P=0.031).Conclusion CENPL has predictive value for HCC recurrence after liver transplantation,which is worthy of further study.
作者 方坚 阮梅 夏磊 黄倩 陈丰穗 张志强 张霞 赖彦华 李懿 吴志贤 周丽丽 FANG Jian;RUAN Mei;XIA Lei(Department of Hepatobiliology,the Third People′s Hospital Affiliated to Fujian University of Traditional Chinese Medicine,Fuzhou 350100,China)
出处 《中国临床新医学》 2022年第12期1147-1152,共6页 CHINESE JOURNAL OF NEW CLINICAL MEDICINE
基金 福建省中青年教师教育科研项目(编号:JAT210142,JAT210143)。
关键词 着丝粒蛋白L 肝细胞癌 肝移植 肿瘤复发 Centromere protein L(CENPL) Hepatocellular carcinoma Liver transplantation Tumor recurrence
  • 相关文献

参考文献7

二级参考文献44

  • 1Nobuhisa Akamatsu,Yasuhiko Sugawara,Norihiro Kokudo.Living-donor vs deceased-donor liver transplantation for patients with hepatocellular carcinoma[J].World Journal of Hepatology,2014,6(9):626-631. 被引量:14
  • 2Mazzaferro V. Regalia E. Doci R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N EnglJ Med. 1996. 334(11) :693-699.
  • 3Zheng SS. Xu X. WuJ. et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008. 85(12):1726-1732.
  • 4Ling Q. Xu X. Wei Q. et al. Downgrading MELD improves the outcomes after liver transplantation in patients with acute?on-chronic hepatitis B liver failure. PLoS One. 2012. 7 (1) : e30322.
  • 5Peng ZH. Xing TH. Dai OJ. et al. Therapeutic effect of liver transplantation on acute liver failure. Zhonghua Yi Xue Za Zhi. 2007. 87(14) :953-955.
  • 6Yuan D. Wei YG. Lin HM. et al. Risk factors of biliary complications following liver transplantation: retrospective analysis of a single centre. Postgrad MedJ. 2009. 85(1001): 119-123.
  • 7Yao FY. Ferrell L. Bass NM. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology , 2001. 33(6): 1394-1403.
  • 8Toso C. Asthana S. Bigam DL. et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology, 2009. 49(3) :832-838.
  • 9Mazzaferro V. LlovetJM. Miceli R. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective. exploratory analysis. Lancet Oncol , 2009. 10(1) :35-43.
  • 10Toso C. Kneteman NM.James SA. et al. The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transpl Int. 2009. 22(9) :869-875.

共引文献98

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部